Summary: Incannex Healthcare Inc provided an update on its lead drug candidate, IHL-42X, an oral therapy in development for the treatment of obstructive sleep apnea (OSA), highlighting progress in its phase 2/3 clinical trial. The clinical trial aims to evaluate IHL-42X in OSA … [Read more...]
Drug Candidate Shows Sleep, RLS Benefits in Parkinson’s Patients
Summary: New data from a period 2A research presented at the XXIX Environment Congress implies that BioVie Inc’s investigational drug bezisterim may greatly enhance rest, reduce tiredness, and ease restless leg signs or symptoms in Parkinson’s condition people when used with … [Read more...]
FDA OKs Phase 1 Trial of Narcolepsy Drug Candidate ORX750
Summary: Centessa Prescription drugs has received Food and drug administration authorization to commence a section 1 demo of ORX750, an investigational oral therapy aimed at narcolepsy and other slumber-wake conditions. ORX750, a selective orexin receptor 2 agonist, addresses the … [Read more...]
Zevra Highlights Plans to Advance IH, Narcolepsy Drug Candidate
Summary: Zevra Therapeutics Inc., in its yr-conclude fiscal and corporate update for 2023, highlighted the development of KP1077 in dealing with idiopathic hypersomnia, citing promising Stage 2 analyze final results. The organization also introduced designs to existing new info … [Read more...]
Zevra Reports Positive Phase 2 Results for IH Drug Candidate
Summary: The stage 2 scientific trial of KP1077 by Zevra Therapeutics for treating idiopathic hypersomnia (IH) has yielded good leading-line effects, confirming the drug’s security and tolerability. KP1077 demonstrated important enhancements in indications these as too much … [Read more...]